Search PubMed⌕ Search

Biomedical subjects

Y Yagami

Publications and source records attributed to Y Yagami.

At least 55 records · Page 3Linked to original sources
PubMed1988

[High-dose CDDP therapy using a balloon-occluded arterial infusion (BOAI) in recurrent ovarian cancer].

An intraarterial high-dose CDDP, using a balloon catheter, has been infused into five patients with a recurrent ovarian cancer. The dose of CDDP was 150 mg-200 mg/body. Two patients experienced a partial tumor regression, whereas three showed no change. With regard to the toxicity, the NAG index (NAG activity/urinary creatinine) rose markedly in all patients, but toxicity was almost similar to that seen from a systemic administration. No significant catheter complication occurred.

Adult↗
PubMed1988

[Pregnancy in patients with chronic glomerulonephritis].

This study was carried out to clarify the effect of pregnancy on chronic glomerulonephritis (CGN). Fifteen patients with CGN diagnosed by renal biopsy were studied throughout 17 pregnancies. The following criteria were adopted: 1) Creatinine clearance (Ccr) over 70 ml/min and serum creatinine (s-Cr) 1.2 mg/dl or less. 2) Blood pressure lower than 140/90 mmHg when not receiving any medicine. 3) No evidence of active progress of nephropathy. In two patients excluded from the criteria, renal function was adversely affected, but there was no evidence that pregnancy affected the natural course of the underlying renal disease. In the patients to which the criteria were applied, the outcome of pregnancy and renal function were good. In conclusion, we recognized that there was no relationship between the body weight of the newborn and maternal serum albumin but that there was a significant correlation between serum uric acid and body weight (r = -0.67). These results show that serum uric acid is a useful indicator of placental dysfunction and fetal growth. In the patients with preeclampsia, the serum uric acid concentration was higher than in the CGN group (8.95 +/- 2.58 mg/dl vs 5.88 +/- 1.49 mg/dl: Scheffe method p less than 0.001). There was no significant difference between the CGN and normal control (5.88 +/- 1.49 mg/dl vs 4.51 +/- 0.68: Scheffe method p less than 0.1). Uric acid serves to distinguish CGN and preeclampsia.

Adult↗
PubMed1987

[Squamous cell carcinoma of the endometrium coexistent with synchronous adenocarcinoma of the cervix].

Primary squamous cell carcinoma of the endometrium is extremely rare. The patient reported here with squamous cell carcinoma of the endometrium and a synchronous adenocarcinoma of the cervix, represents an extreme, unique example of multiple Müllerian neoplasms. The 70-year-old female had a three-month history of vaginal bleeding. On July 13, 1984, she underwent a radical hysterectomy with a pelvic lymphadenectomy. A histological examination substantiated keratinizing squamous cell carcinoma of the endometrium this tumor extending outside the uterus, and an adenocarcinoma of the cervix. Post-operatively she received chemotherapy and irradiation therapy, but metastases reoccurred and she died on December 1, 1984.

Adenocarcinoma↗
PubMed1987

[Preeclampsia and tubular dysfunction].

Renal involvement associated with preeclampsia is well investigated, especially from the aspect of glomerular lesion and coagulation. On the other hand, only a few studies on tubular dysfunction during normal pregnancy and preeclampsia have been reported. The first study was carried out to clarify and estimate the chronological changes in tubular function. Pregnant women without obvious tubular dysfunction and toxemia (group A) were investigated using serum Cl, Na minus Cl (Na-Cl index), uric acid and urinary beta 2-microglobulin (u-beta-MG) at the 10th, 20th, 30th and 36th weeks of gestation. The second study was carried out to determine the significance of tubular dysfunction accompanied by preeclampsia. Patients with severe preeclampsia (group B) and normal pregnancy (group C) were examined by the same index of tubular dysfunction. The diagnosis of severe preeclampsia was confirmed with hypertension (over 170/110 mmHg), proteinuria (beyond 3 g/day) and severe edema. The following results were obtained: Urinary beta-MG and serum Cl increased during the third trimester in group A, but the Na-Cl index decreased. The serum uric acid concentration increased during the third trimester in group A. Tubular dysfunction was evident during the third trimester in normal pregnancy. Every index of tubular dysfunction including u-beta-MG, serum Cl, Na-Cl index and uric acid in group B was significantly higher than in group C. In group B, 4 fetuses died and 7 out of 15 cases required Cesarean sections. The critical line of tubular dysfunction for fetal prognosis was Cl 110 mEq/l, Na-Cl index 28 mEq/l, uric acid 6.0 mg/dl and u-beta-MG 1,000 micrograms/l.(ABSTRACT TRUNCATED AT 250 WORDS)

Chlorine↗
PubMed1987

[Antitumor effects of the tumor necrosis factor (PAC-4D) against human gynecological carcinoma transplanted into nude mice].

The antitumor effects of human recombinant TNF (PAC-4D) were examined on three human gynecological carcinomas transplanted into CD-1 nude mice (uterine cervical carcinoma: UZ-1-N; ovarian carcinoma: OCl-1-N and OS-4-N). PAC-4D was administered intratumorally at a dose of 1,000 U, 3,000 U or 10,000 U/head from day 0 to day 4. Tumor size, body weight and peripheral WBC were measured on days 0, 4, 8, 12 and 16 and histological studies were made on day 6. The results were as follows: With UZ-1-N, intratumoral administration of PAC-4D at doses of 3,000 U and 10,000 U/head caused a marked inhibition of the tumor growth. Similarly, antitumor activity of PAC-4D against OCl-1-N was remarkable at a dose of 10,000 U/head. The administration of PAC-4D at doses of 3,000 U and 10,000 U/head was not effective against OS-4-N. The histological changes of grade II A-B by Ohboshi-Shimosato criteria of response were observed in the tumor of the effective groups against PAC-4D. There were no influences on the body weight and WBC after administration of PAC-4D. Although tumor cells possessed different sensitivities to PAC-4D, PAC-4D is strongly recommended for the treatment of gynecological malignancies.

Animals↗
PubMed1986

[Anencephalus immunogenetic factor].

The T/t complex in the mouse is considered to be a gene locus that brings about neural tube defects. This locus is found to exist near the H-2 complex, which is the MHC of the mouse. Accordingly, it is conceivable that there exists a T/t-like complex near the HLA complex in humans. Studies on the HLA-A, -B, -DR, -DRw52, -53 and DQ loci of parents with anencephalus and affected offspring were undertaken with the aim of revealing the relationship between anencephalus and the HLA complex. The following results were obtained: The gene frequency of HLA-DR5 in a mother with anencephalus was significantly higher than in controls. HLA-DR materno-paternal compatibility was significantly higher than in control couples. An increase in HLA-DR, -DRw52, -53 and DQ homozygosity were observed among the affected offspring. These results indicated that there may exist an anencephalus immunogenetic factor in the HLA-D region.

Adult↗
PubMed1986

[The effect of immunochemotherapy with PSK in malignant tumors of the female reproductive organs].

In our series of investigations concerning immunopotentiators, we evaluated the host immunocompetence of patients triggered by PSK. Our subjects for screening consisted of seven patients with malignant tumors of female reproductive organs chosen at random from our patients. Four of them were treated with chemotherapy (CAPF) alone and served as controls, whereas the other three were administered PSK, 3.0 g/day, plus chemotherapy as above. Cellular and humoral immunities were measured at three points. Firstly prior to chemotherapy, secondly, two weeks after the start of chemotherapy, and thirdly, prior to next chemotherapy. The results indicated higher values of T-cell subset ratio OKT-4/8 of 2.73 +/- 0.56 on the average for cellular immunocompetence as compared to 1.35 +/- 0.45 for normal subjects in the PSK-administered group, whereas there was no increase in the non-PSK-administered group, in which the value was 1.28 +/- 0.30. Thus, PSK was considered to extert an immunopotentiating effect on the T-lymphocytes.

Adjuvants, Immunologic↗
PubMed1986

[Comparative studies of antitumor activities of oxalate (1R, 2R-cyclohexanediammine) platinum (II) and cis-dichlorodiammine-platinum (II) using ovarian cancer transplanted into nude mice].

A new platinum coordination complex, l-OHP [oxalato (1R, 2R-cyclohexanediammine) platinum (II)], has been shown to be an active anticancer agent in animals. In the present study comparisons of the effects on human ovarian carcinomas transplanted into nude mice (OCl-1-N, OS-4-N, OY-1-N) between l-OHP and CDDP, were investigated. l-OHP (6 mg/kg, 9 mg/kg) and CDDP (3 mg/kg, 6 mg/kg) were administered intraperitoneally in a schedule of every four days for three doses. Simultaneously the tumor size and the body weight were measured and the peripheral WBC and serum BUN were examined. The results were as follows: 1) The antitumor activity of l-OHP corresponded to that of CDDP in proportion to the Pt content and mouse LD50. 2) In l-OHP, there was no elevation of the BUN value and less decrease in body weight, but the peripheral leukopenia was more severe, although reversible. l-OHP is an active anticancer agent against xenografts in nude mice and is strongly recommended for clinical application.

Animals↗
PubMed1985

[Combination chemotherapy with peplomycin, cis-platinum and mitomycin C in gynecologic cancer].

Eight patients with gynecologic cancer (cervix: 6, corpus: 1 and vulva: 1) were treated with combination chemotherapy, PPM therapy consisting of continuously infused PEP 4mg/m2 days 1-5, CDDP 13 mg/m2 days 1-5, and MMC 3mg/m2 day 1. This was repeated every three to five weeks. Six of the eight patients were evaluable, two had a complete response and one had a partial response, for an overall response rate of 50%. Because of hematological toxicity, blood transfusion was carried out in four patients. Nephrotoxicity and pulmonary toxicity were slight. Nausea and vomiting were controlled with dexamethasone and domperidone. PPM therapy is considered to be an effective and useful combination chemotherapy for patients with gynecologic cancer.

Adenocarcinoma↗
PubMed1985

[Fundamental and clinical studies on aztreonam in the gynecological field].

Aztreonam (AZT), a new monocyclic beta-lactam antibiotic was studied on clinical efficacy for infectious disease in gynecological field. At about 80 minutes following intravenous injection of 1 g dose of AZT, it penetrated well into internal genital organs at therapeutic levels. Moreover it transferred very fast and enough into intrapelvic dead space exudate, and its level was kept still as high at 12 hours after administration. AZT was given to 20 women affected with gynecological infectious disease. The outcome of AZT therapy was as follows: effective in 5 out of 6 patients (83.3%) administered intravenously and in all of 14 patients (100%) received intramuscularly. Notable adverse effects or abnormal laboratory findings were not observed except 1 case of diarrhea and 2 cases of transient and slight elevation of serum CPK and transaminases. Based on these results, we may conclude that AZT is a highly effective and a very safe antibiotic for the treatment of infectious disease in gynecological field.

Adult↗
PubMed1985

A preliminary study on rabbit tubal anastomosis with the Nd-YAG laser.

This is the first report on the use of the Nd-YAG laser in performing tubal end to end anastomosis in rabbit. At first, the optimal intensity of laser exposure was evaluated using histological preparations of tubal ampullary tissues which were exposed in various conditions. It was determined that the most suitable condition was 12 watts/cm2 of energy density of 0.2 second duration and a 0.6mm focal spot. Subsequently, these treatment conditions were applied practically to end end anastomosis of severed tubal ampulla of three rabbits. Four weeks later, the second laparotomy was done to confirm the restoration of tubal patency by chromopertubation in vivo, and to excise the restored tube to study the reconstruction of luminal epithelium histologically by scanning electron microscope. Proven by chromopertubation in vivo, tubal patency was restored in 4 out of 6 tubal samples, but in two, tubes were dehisced at the anastomosed line. By scanning electron microscopic observation of tubal samples in which patency was restored some injury to mucosal epithelial cells was seen at the anastomosed site. It is concluded that the Nd-YAG laser technique is useful in tubal end to end anastomosis of rabbit and accurate placement of tubal stumps is essential to the proper restoration of tubal patency.

Animals↗
PubMed1985

[The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].

Serum CA125 levels were measured by radioimmunoassay patients with various gynecological tumors. Elevated levels of CA125 were detected in the serum of patients with malignant ovarian tumors. Among patients with uterine tumors, CA125 levels were elevated in those with malignant uterine tumors, but not with uterine myomas. The correlations between tumor markers (CA125, IAP, ferritin, PTA) and malignant ovarian tumors were measured, and only CA125 levels were found to correlate with progression or regression of the disease in patients with malignant ovarian tumors. These results suggest that CA125 may be a useful marker for monitoring the response to treatment in patients with malignant ovarian tumors.

Adenocarcinoma↗